BofA warns Fed risks policy mistake with early rate cuts
Janet Napolitano, a director at Vir Biotechnology, Inc. (NASDAQ:VIR), recently executed several transactions involving the company’s common stock. According to a recent SEC filing, Napolitano sold 3,200 shares on June 2, 2025, at an average price of approximately $5.05 per share, totaling $16,148. The sale price represents a significant discount from the stock’s 52-week high of $14.45, though the shares have recently shown strength with a 12.67% gain over the past week. This sale was conducted under a pre-established Rule 10b5-1 trading plan.
Additionally, on May 30, 2025, Napolitano acquired 8,000 restricted stock units (RSUs) as part of Vir Biotechnology’s Equity Incentive Plan, with these units set to vest on May 30, 2026. On the same day, she also received stock options for 16,000 shares, which will become exercisable in full by May 30, 2026. These acquisitions were recorded with no associated cost per share. Notably, analysts maintain price targets ranging from $12 to $31 for the stock, suggesting potential upside from current levels.
Following these transactions, Napolitano holds 16,416 shares of Vir Biotechnology’s common stock directly. According to InvestingPro analysis, while the company maintains a strong balance sheet with more cash than debt, its overall financial health score is currently rated as WEAK. For deeper insights into VIR’s valuation and 12 additional ProTips, including detailed analyst forecasts and financial health metrics, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Vir Biotechnology reported its first-quarter 2025 financial results, revealing a slight miss in earnings per share (EPS) forecasts and a significant shortfall in revenue projections. The company’s EPS was recorded at -$0.88, slightly below the forecast of -$0.87, while revenue came in at $3.03 million, considerably less than the expected $13.65 million. This earnings report highlighted increased research and development expenses, which rose to $118.6 million from $100.1 million in the previous year, reflecting Vir’s ongoing focus on its Hepatitis Delta and oncology programs. Additionally, H.C. Wainwright adjusted its price target for Vir Biotechnology shares, reducing it to $15 from the previous $110, following the release of data from the Phase 2 MARCH study on chronic hepatitis B virus treatment. Despite this setback, H.C. Wainwright maintained a Buy rating, citing the potential of Vir’s ongoing work in other areas, particularly the ECLIPSE 1 Phase 3 trial for chronic hepatitis delta virus treatment. Moreover, Vir’s oncology pipeline is showing promise, with T-cell engager programs demonstrating early efficacy and safety in solid tumors. The company also holds a strong financial position, with approximately $1.02 billion in cash, providing a runway into mid-2027. These recent developments indicate Vir’s commitment to advancing its pipeline and addressing significant unmet medical needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.